CN1450997A - 含铜的胺氧化酶的抑制剂 - Google Patents

含铜的胺氧化酶的抑制剂 Download PDF

Info

Publication number
CN1450997A
CN1450997A CN01815101A CN01815101A CN1450997A CN 1450997 A CN1450997 A CN 1450997A CN 01815101 A CN01815101 A CN 01815101A CN 01815101 A CN01815101 A CN 01815101A CN 1450997 A CN1450997 A CN 1450997A
Authority
CN
China
Prior art keywords
alkyl
aryl
optionally substituted
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01815101A
Other languages
English (en)
Chinese (zh)
Inventor
D·J·史密斯
M·亚尔卡宁
F·费勒普
L·拉扎
Z·斯扎康伊
G·贝尔纳斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotie Therapies Corp
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Publication of CN1450997A publication Critical patent/CN1450997A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN01815101A 2000-07-05 2001-07-04 含铜的胺氧化酶的抑制剂 Pending CN1450997A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21634100P 2000-07-05 2000-07-05
US60/216,341 2000-07-05

Publications (1)

Publication Number Publication Date
CN1450997A true CN1450997A (zh) 2003-10-22

Family

ID=22806663

Family Applications (2)

Application Number Title Priority Date Filing Date
CN01815101A Pending CN1450997A (zh) 2000-07-05 2001-07-04 含铜的胺氧化酶的抑制剂
CN01815102A Pending CN1450998A (zh) 2000-07-05 2001-07-04 含铜的胺氧化酶的抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN01815102A Pending CN1450998A (zh) 2000-07-05 2001-07-04 含铜的胺氧化酶的抑制剂

Country Status (14)

Country Link
US (2) US6624202B2 (https=)
EP (2) EP1301495A2 (https=)
JP (2) JP2004502682A (https=)
CN (2) CN1450997A (https=)
AU (3) AU2001282162A1 (https=)
CA (2) CA2414807A1 (https=)
HU (2) HUP0301625A3 (https=)
IL (2) IL153767A0 (https=)
NO (2) NO20026283L (https=)
NZ (2) NZ523463A (https=)
PL (2) PL360353A1 (https=)
RU (2) RU2003103291A (https=)
WO (2) WO2002002090A2 (https=)
ZA (2) ZA200300063B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109810041A (zh) * 2017-11-21 2019-05-28 南京药捷安康生物科技有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502682A (ja) 2000-07-05 2004-01-29 バイオティ　セラピーズ　コーポレイション 銅含有アミン・オキシダーゼの阻害剤
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
AR042941A1 (es) 2003-01-27 2005-07-06 Fujisawa Pharmaceutical Co Derivados de tiazol, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos inhibidores de la proteina-1 de adhesion vascular (vap-1)
US20060229346A1 (en) * 2003-03-31 2006-10-12 Sucampo Ag Method for treating vascular hyperpermeable disease
ATE447610T1 (de) * 2003-05-26 2009-11-15 Biotie Therapies Corp Kristalliner vap-1 und verwendung
FI20031927A0 (fi) * 2003-12-31 2003-12-31 Faron Pharmaceuticals Oy Terapeuttisesti vaikuttavia aineita ja niiden käyttö
FI20040136A0 (fi) * 2004-01-30 2004-01-30 Faron Pharmaceuticals Oy Erityisesti diabeetikoille soveltuvia koostumuksia
SI1708711T1 (sl) * 2004-01-30 2010-07-30 Biotie Therapies Oyj Spojine uporabne posebno za zdravljenje ali prepreäśevanje metaboliäśnega sindroma
US8119651B2 (en) 2004-01-30 2012-02-21 Biotie Therapies Corp. Compositions useful especially for treatment or prevention of metabolic syndrome
FI20040270A0 (fi) * 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset
CN101031555A (zh) * 2004-07-27 2007-09-05 安斯泰来制药有限公司 具有vap－1抑制活性的噻唑衍生物
WO2006028269A2 (en) * 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 ihibitory activity
JP4140630B2 (ja) * 2005-11-10 2008-08-27 Ｔｄｋ株式会社 磁気ヘッドアセンブリ及び磁気ヘッドアセンブリの製造方法
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
FI20061156A0 (fi) 2006-12-27 2006-12-27 Elina Kivi Uusia peptidejä
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
CN101917845A (zh) 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
TWI437986B (zh) 2008-01-31 2014-05-21 R Tech Ueno Ltd 噻唑衍生物及使用該衍生物作為ｖａｐ－１抑制劑之用途
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
WO2010026272A1 (es) 2008-09-03 2010-03-11 Universitat Autònoma De Barcelona Métodos y composiciones para el tratamiento y el diagnóstico de la transformación hemorrágica
RU2400233C1 (ru) 2009-07-07 2010-09-27 Общество с ограниченной ответственностью "Вирфарм" Способ лечения заболеваний печени различного генеза
UA112154C2 (uk) * 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
PL2479165T3 (pl) 2009-09-16 2018-05-30 Astellas Pharma Inc. Związek glicynowy
RU2010145439A (ru) 2010-11-08 2012-05-20 Виктор Вениаминович Тец (RU) Средство для лечения поражений печени, вызванных воздействием химических или биологических агентов
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
LT3002278T (lt) 2011-03-15 2017-06-26 Astellas Pharma Inc. Guanidino junginys
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
EP3131539B1 (en) 2014-04-15 2018-12-05 Pécsi Tudományegyetem Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
RU2595868C1 (ru) 2015-03-27 2016-08-27 Виктор Вениаминович Тец Лекарственное средство с гепатопротекторной активностью
JP2018076236A (ja) 2015-06-05 2018-05-17 株式会社アールテック・ウエノ がんを処置するための医薬組成物
WO2017098236A1 (en) 2015-12-07 2017-06-15 Proximagen Limited Vap-1 inhibitors for treating pain

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3377345A (en) * 1966-09-23 1968-04-09 Dow Chemical Co Substituted 3, 4, 5, 6-tetrahydro-2h-1, 3, 4-oxadiazin-2-one compounds and method ofpreparation thereof
US3486916A (en) 1966-12-22 1969-12-30 William A Cordon Cement mixes and the production of articles therefrom
SE320311B (https=) 1968-07-15 1970-02-02 Mo Och Domsjoe Ab
WO1993023023A1 (en) * 1992-05-15 1993-11-25 University Of Saskatchewan Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis
US5413634A (en) 1993-08-06 1995-05-09 Arco Chemical Technology, L.P. Cement composition
CA2117585C (en) 1993-09-14 2001-06-05 Edward T. Shawl Cement composition
AU2696795A (en) 1994-08-25 1996-03-14 W.R. Grace & Co.-Conn. Shrinkage reduction cement composition
US5618344A (en) 1995-03-06 1997-04-08 W. R. Grace & Co.-Conn. Cement composition
US5556460A (en) 1995-09-18 1996-09-17 W.R. Grace & Co.-Conn. Drying shrinkage cement admixture
US5603760A (en) 1995-09-18 1997-02-18 W. R. Grace & Co.-Conn. Cement admixture capable of inhibiting drying shrinkage and method of using same
JP2004502682A (ja) 2000-07-05 2004-01-29 バイオティ　セラピーズ　コーポレイション 銅含有アミン・オキシダーゼの阻害剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109810041A (zh) * 2017-11-21 2019-05-28 南京药捷安康生物科技有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用

Also Published As

Publication number Publication date
RU2003103286A (ru) 2004-08-20
IL153767A0 (en) 2003-07-06
US20020173521A1 (en) 2002-11-21
PL360353A1 (en) 2004-09-06
NO20026283L (no) 2003-02-28
US6624202B2 (en) 2003-09-23
HUP0301625A3 (en) 2005-04-28
ZA200300063B (en) 2003-07-22
CA2414807A1 (en) 2002-01-10
WO2002002090A3 (en) 2002-05-16
PL360374A1 (en) 2004-09-06
AU8216301A (en) 2002-01-14
NZ523463A (en) 2004-06-25
US20040106654A1 (en) 2004-06-03
NO20026282L (no) 2003-03-03
NO20026282D0 (no) 2002-12-30
JP2004502682A (ja) 2004-01-29
EP1313718A2 (en) 2003-05-28
AU2001282163B2 (en) 2004-12-09
HUP0301625A2 (hu) 2003-11-28
WO2002002541A2 (en) 2002-01-10
CA2414799A1 (en) 2002-01-10
HUP0301336A3 (en) 2005-04-28
NO20026283D0 (no) 2002-12-30
NZ523464A (en) 2003-10-31
EP1301495A2 (en) 2003-04-16
IL153766A0 (en) 2003-07-06
CN1450998A (zh) 2003-10-22
RU2003103291A (ru) 2005-01-27
AU2001282162A1 (en) 2002-01-14
HUP0301336A2 (hu) 2003-08-28
JP2004501962A (ja) 2004-01-22
WO2002002090A2 (en) 2002-01-10
ZA200300064B (en) 2003-07-22
WO2002002541A3 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
CN1450997A (zh) 含铜的胺氧化酶的抑制剂
JP4377221B2 (ja) 銅含有アミン・オキシダーゼの炭素環ヒドラジノ阻害剤
AU2001282163A1 (en) Inhibitors of copper-containing amine oxidases
CN1630636A (zh) 二氢吲哚衍生物及其作为5－ht2受体配体的用途
CN1364157A (zh) N－(吲哚羰基)哌嗪衍生物
CN85101761A (zh) 新型色胺衍生物的制备方法和应用
EP2521714B1 (en) Aromatic sulfone compounds useful in the treatment of central nervous disorders
WO2023141595A2 (en) Functionalized alkylamines
CN1819822A (zh) 含有取代喹啉和取代二苯砜的组合物以及使用方法
CA2376876C (fr) Nouveaux derives d&#39;isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN102317261B (zh) 三重再摄取抑制剂及其应用方法
CA2378628C (fr) Nouveaux derives d&#39;indenoindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017183723A1 (ja) Ｋｃｎｑ２～５チャネル活性化剤
CN1125946A (zh) 用作炎症前细胞因子选择性抑制剂的新的碳环核苷药物
HK1058794A (en) Inhibitors of copper-containing amine oxidases
CN1960986A (zh) 丁酰胆碱酯酶选择性抑制剂
HK1064957A (en) Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
JP2021509398A (ja) 二重作用ｆｋｂｐ１２およびｆｋｂｐ５２阻害剤
AU2002354626A1 (en) Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
ZA200500952B (en) 3,6 Disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonists.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned